65 Meta-analysis and systematic review of coronary vasospasm in ANOCA patients Mean age (years) ±SD Female n (%) Control group Diagnostic agent Diagnosis spasm Dosages 60.5±8.9 31 (62) NA Ach >75% spasm, symptoms & ischemic ECG 2,20,100,200 ug 3 min ic into LAD 61.9±11.1 806 (58.4) AP Ach >75% spasm, symptoms & ischemic ECG 2,20,100,200 ug 3 min ic into LAD 53.6±9.3 71 (25.6) NA Ergo >50% spasm, without additional criteria 1,2,3,6 ug/kg-1 injection 51.3 106 (94.6) oCAD Ergo >75% spasm, without additional criteria 0.1, 0.2, 0.3mg bolus into ascending aorta 54±11 53 (32.7) NA Ergo >50% spasm, without additional criteria 1,5,10,30 ug 1 min ic into RCA, LAD 55.5±10.3 284 (43.2) AP Ergo & Ach >50% spasm, without additional criteria and/ or transient ST segment changes during pain Ergo: 0,05 mg up to 0.85mg iv; Ach 20,50,100 ug ic 60.9±10.0 111 (73.5) AP Ach >90% spasm, symptoms & ischemic ECG 100 ug bolus ic into LAD, 50 ug bolus ic into RCA 46±9 43 (39.9) NA Ergo >75% spasm, without additional criteria 50,100, 200 ug 3min iv and 25 ug ic 58±8 228 (86.4) NA Ach >90% spasm, symptoms & ischemic ECG 2,20,100,200 ug 1-3 min ic into LAD 56.4 357 (49.7) NA Ach >50% spasm, without additional criteria NR 50±9 27 (22.5) oCAD, HC Ergo >75% spasm, symptoms & ischemic ECG 0.04, 0.16, 0.2 mg 53.9±11.0 38 (78) NA Ach >90% spasm, symptoms & ischemic ECG 25,50,100 ug bolus 20sec ic into LM 4
RkJQdWJsaXNoZXIy MTk4NDMw